GLP‑1 access is fracturing

These drugs started as a shortage story, but by April 2026 they had turned into a rules fight over who can sell them, who can pay for them, and which patients will actually benefit. The Food and Drug Administration said on February 21, 2025 that the semaglutide injection shortage was resolved, which removed the main legal opening many compounders had used to make copycat versions. (fda.gov) Glucagon-like peptide 1 drugs work by copying a gut hormone that tells the brain you are full and slows how fast food leaves the stomach. Semaglutide is the ingredient in Wegovy and Ozempic, and tirzepatide is the ingredient in Zepbound and Mounjaro, so one family of injections now sits in both the obesity market and the diabetes market at once. (wpde.com) Compounding used to be the pressure valve when branded pens were hard to find, because pharmacies can mix versions of a drug for patients when commercial supply breaks down. Once the shortage designation ended, the Food and Drug Administration said outsourcing facilities making compounded semaglutide would lose that protection after May 22, 2025, even though the agency said it could still act sooner on unsafe or substandard products. (fda.gov) That pushed the fight onto telehealth sites and online ads. Pharmacy Times reported that on September 16, 2025 the Food and Drug Administration sent more than 55 warning letters to online sellers of compounded glucagon-like peptide 1 drugs over misleading direct-to-consumer marketing, and regulators later signaled broader restrictions on mass-marketed compounded versions. (pharmacytimes.com, pharmacytimes.com) Novo Nordisk is not just arguing about ads. The company has also gone after telehealth and compounding channels in court and in public warnings, trying to pull patients back toward branded Wegovy as the legal room for copycat semaglutide narrows. (pharmacytimes.com, spencerfane.com) At the same time, the science is getting less one-size-fits-all. A study published in Nature found that common genetic variants in GLP1R and GIPR, the genes that encode the drug targets, were linked to differences in both weight loss and side effects such as nausea and vomiting. (nature.com, nature.com) That means two people can take the same weekly shot at the same dose and get very different results for reasons that start in their DNA. The 23andMe Research Institute said the findings point toward precision prescribing, where doctors could eventually use genetic clues the way a mechanic uses a diagnostic scan before swapping a part. (news-medical.net, nature.com) Insurance is now the next bottleneck. Insurance Business reported that in a survey of more than 2,130 Americans age 65 and older, 82% had not heard that Medicare is rolling out a model to enable obesity-drug access and 81.5% had not heard that glucagon-like peptide 1 drugs could become available through that structure. (insurancebusinessmag.com) The model is called BALANCE, and it only moves forward for the 2027 plan year if 80% of Medicare Part D prescription drug plans choose to participate. Applications are due April 20, 2026, the Centers for Medicare and Medicaid Services will decide by April 30, 2026 whether that threshold was met, and coverage would start January 1, 2027 if the model is approved. (insurancebusinessmag.com) So the market is splitting three ways at once. Regulators are squeezing compounded supply, drugmakers are defending branded channels, and researchers are showing that “does it work” may soon depend as much on a patient’s genes as on whether the prescription can be filled. (fda.gov, nature.com, insurancebusinessmag.com)